Loading…
Exelixis, Inc. is projected to rise to $84.19 by 2027, a +49% move from its current price of $56.50. EXEL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 15 | $55.63 | $56.54 | $57.47 | +0.07% |
| Jul 16 | $55.29 | $56.58 | $57.90 | +0.14% |
| Jul 17 | $55.04 | $56.62 | $58.24 | +0.21% |
| Jul 18 | $54.84 | $56.66 | $58.53 | +0.28% |
| Jul 19 | $54.67 | $56.70 | $58.80 | +0.35% |
| Jul 20 | $54.52 | $56.74 | $59.05 | +0.42% |
| Jul 21 | $54.38 | $56.78 | $59.28 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $54.38 | $56.78 | $59.28 | +0.49% |
| Week 2 | $53.68 | $57.05 | $60.64 | +0.98% |
| Week 3 | $53.20 | $57.33 | $61.77 | +1.47% |
| Week 4 | $52.85 | $57.61 | $62.80 | +1.96% |
| Week 5 | $52.57 | $57.89 | $63.75 | +2.46% |
| Week 6 | $52.34 | $58.17 | $64.65 | +2.96% |
| Week 7 | $52.15 | $58.45 | $65.52 | +3.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Exelixis, Inc. is an oncology company focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. Its CABOMETYX tablets are for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules are for the treatment of progressive and metastatic medullary thyroid cancer.
CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Exelixis, Inc. (EXEL) is currently priced at $55.85 with a market capitalization of $14.04B and a market rank of 716. The stock sits within a healthcare-focused landscape and maintains a steady near-term profile as reflected in its price action and forecasts.
The multi-year forecast points to meaningful upside, with the 2026 average price at $55.85 and a path higher to $126.88 by 2030 and ultimately to $888.72 by 2050, while the maximums underscore substantial upside potential to $1,453.34 in 2050.
The forecast also shows a gradual expansion in expected value over time, with a 2026 min of $40.74 and a 2026 max of $76.61, and a progressive rise through 2030 ($99.08 to $173.03 range for min/max), 2040 ($335.92 to $721.81 range), and 2050 ($588.38 to $1,453.34 range). The overall sentiment attached to the projected path is bullish across the longer horizon.
A major floor 27.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.1% below — buyers have tended to step in here.
Price is pressing into resistance (1.1% away) — a breakout level to watch.
A major ceiling 10.8% above — clearing it would confirm fresh momentum.
Key EXEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EXEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $56.46 | Buy | $56.31 | Buy |
| MA 10 | $55.56 | Buy | $55.55 | Buy |
| MA 20 | $54.02 | Buy | $54.32 | Buy |
| MA 50 | $51.19 | Buy | $51.58 | Buy |
| MA 100 | $47.25 | Buy | $48.75 | Buy |
| MA 200 | $44.60 | Buy | $45.61 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.52 | Neutral |
| Stoch RSI (14) | 64.40 | Neutral |
| CCI (20) | 107.07 | Buy |
| Williams %R (14) | -10.42 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 10.05 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 89.58 | Sell |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 3.67 | Buy |
| Ultimate (7,14,28) | 66.42 | Neutral |
| Momentum (10) | 3.27 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 57.20 | Sell |
| ADX (14) | 24.08 | Buy |
| ATR (14) | 0.83 | Info |
The near-term picture for Exelixis appears bullish with RSI(14) at 70. The stock is trading above its 50-day simple moving average of $50.10 and above its 200-day simple moving average of $44.18, signaling positive momentum. The 30-day range spans from a low of $49.93 to a high of $62.47, giving a defined band for near-term movement.
Support is identified at $48.54 and resistance at $55.85, framing a constructive setup in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $40.74 | $56.50 | $78.13 | 0% | Neutral | |
| $68.96 | $84.19 | $107.46 | +49% | Bullish | |
| $81.00 | $100.75 | $132.08 | +78% | Bullish | |
| $93.92 | $118.63 | $158.83 | +110% | Bullish | |
| $106.02 | $135.72 | $185.00 | +140% | Bullish | |
| $119.38 | $154.68 | $214.17 | +174% | Bullish | |
| $151.01 | $197.88 | $277.88 | +250% | Bullish | |
| $182.37 | $241.50 | $343.54 | +327% | Bullish | |
| $204.06 | $272.91 | $392.85 | +383% | Bullish | |
| $219.25 | $296.00 | $430.84 | +424% | Bullish | |
| $395.09 | $556.33 | $848.58 | +885% | Bullish | |
| $716.90 | $1,082.66 | $1,770.20 | +18.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $40.74 | $56.50 | $68.78 | +0.00% |
| August 2026 | $50.71 | $59.35 | $70.94 | +5.04% |
| September 2026 | $51.19 | $60.19 | $72.52 | +1.43% |
| October 2026 | $53.08 | $62.68 | $76.02 | +4.13% |
| November 2026 | $54.15 | $64.17 | $78.26 | +2.38% |
| December 2026 | $53.61 | $63.74 | $78.13 | -0.67% |
Click any year to see its month-by-month EXEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, EXEL could reach as high as $78.13, with a base case around $56.50 and support toward $40.74 — roughly 0% from $56.50. A consolidation phase looks the most probable path here.
Expect EXEL to range from $68.96 to $107.46 through 2027. The $84.19 average target implies a +49% move from current prices. That is up +49% on the projected 2026 average. Momentum favours further upside here.
The EXEL price prediction for 2028 points to an average of $100.75 (low $81.00, high $132.08) — a potential gain of +78% on today's $56.50. Buyers look set to stay in control over this stretch.
In 2029, EXEL is projected to trade between $93.92 and $158.83, averaging $118.63 — a potential gain of +110% from today's $56.50. That is up +18% on the projected 2028 average. Momentum favours further upside here.
Exelixis, Inc.'s 2030 outlook centres on $135.72, within a $106.02 to $185.00 range. That is up +14% on the projected 2029 average. That marks a +140% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, EXEL could reach as high as $214.17, with a base case around $154.68 and support toward $119.38 — roughly +174% from $56.50. Momentum favours further upside here.
Expect EXEL to range from $151.01 to $277.88 through 2032. The $197.88 average target implies a +250% move from current prices. That is up +28% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The EXEL price prediction for 2033 points to an average of $241.50 (low $182.37, high $343.54) — a potential gain of +327% on today's $56.50. Momentum favours further upside here.
In 2034, EXEL is projected to trade between $204.06 and $392.85, averaging $272.91 — a potential gain of +383% from today's $56.50. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Exelixis, Inc.'s 2035 outlook centres on $296.00, within a $219.25 to $430.84 range. That is up +8% on the projected 2034 average. That marks a +424% change versus current levels. Momentum favours further upside here.
By 2040, EXEL could reach as high as $848.58, with a base case around $556.33 and support toward $395.09 — roughly +885% from $56.50. Buyers look set to stay in control over this stretch.
Expect EXEL to range from $716.90 to $1,770.20 through 2050. The $1,082.66 average target implies a +18.2x move from current prices. That is up +95% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in EXEL today (≈ 17.699115 EXEL) could be worth
$19,162.15
+$18,162.15 (+1816%) by 2050 · US Dollar
Based on the average projected EXEL price of $1,082.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EXELwould be worth at today's price.
$1,000 invested in EXEL on Jul 10, 2025 (≈ 22.138588 EXEL) would be worth
$1,250.83
+$250.83 (+25.1%) today · 1.25× · US Dollar
Based on a EXEL entry price of $45.17 vs. today's $56.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $55.85 | $1,011.64 | +1.2% |
| 1 month ago | $52.58 | $1,074.55 | +7.5% |
| 3 months ago | $44.27 | $1,276.26 | +27.6% |
| 6 months ago | $44.06 | $1,282.34 | +28.2% |
| 1 year ago | $45.17 | $1,250.83 | +25.1% |
| All time (5.0y) ago | $17.41 | $3,245.26 | +224.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EXEL forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $27.65B
The multi-year forecast shows bullish sentiment across the horizon, with the 2030 average price at $126.88 and a 2030 ROI of 127.2, the 2040 average at $473.11 with an ROI of 747.1, and the 2050 average at $888.72 with an ROI of 1491.3. The path to 2030, 2040, and 2050 reflects meaningful upside from current levels, signaling substantial long-run appreciation potential. Across these years, the max forecast reaches as high as $1,453.34 by 2050, illustrating the scale of the upside if targets are met.
These figures come with bullish sentiment for the longer horizon, but are estimates and subject to market conditions and other risks inherent in forecasting.
Tap a question to reveal the answer.
2030 avg $126.88, min $99.08, max $173.03, roiPct 127.2, sentiment BULLISH.
The forecast shows bullish sentiment in multiple years with rising averages, including 2030 avg $126.88 (ROI 127.2) and 2050 avg $888.72 (ROI 1491.3), suggesting upside potential within the provided estimates.
2033 avg $218.07, which implies the average price would be above $200 in 2033.
Current price is $55.85 and market cap is $14.04B.
Near term is bullish with RSI(14) at 70. The 30-day range is $49.93 to $62.47, with support at $48.54 and resistance at $55.85.
Exelixis, Inc. Community Discussion
0Share your Exelixis, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.